Roche Holding AG (RO) - Total Assets
Based on the latest financial reports, Roche Holding AG (RO) holds total assets worth CHF98.20 Billion CHF (≈ $124.15 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Roche Holding AG - Total Assets Trend (1998–2025)
This chart illustrates how Roche Holding AG's total assets have evolved over time, based on quarterly financial data. Also see Roche Holding AG stock valuation for the company's overall valuation and market capitalisation.
Roche Holding AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Roche Holding AG's total assets of CHF98.20 Billion consist of 38.5% current assets and 61.5% non-current assets. Review Roche Holding AG (RO) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF1.51 Billion | 5.5% |
| Accounts Receivable | CHF11.90 Billion | 11.8% |
| Inventory | CHF7.48 Billion | 7.4% |
| Property, Plant & Equipment | CHF22.93 Billion | 22.8% |
| Intangible Assets | CHF19.32 Billion | 19.2% |
| Goodwill | CHF7.49 Billion | 7.4% |
Asset Composition Trend (1998–2025)
This chart illustrates how Roche Holding AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See RO share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Roche Holding AG's current assets represent 38.5% of total assets in 2025, a decrease from 50.0% in 1998.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2025, up from 3.6% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is property, plant & equipment at 22.8% of total assets.
Roche Holding AG Competitors by Total Assets
Key competitors of Roche Holding AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
Roche Holding AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.23 | 1.29 | 1.24 |
| Quick Ratio | 0.95 | 1.02 | 0.91 |
| Cash Ratio | 0.00 | 0.27 | 0.20 |
| Working Capital | CHF6.59 Billion | CHF8.12 Billion | CHF6.07 Billion |
Roche Holding AG - Advanced Valuation Insights
This section examines the relationship between Roche Holding AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.79 |
| Latest Market Cap to Assets Ratio | 0.49 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | CHF100.70 Billion |
| Market Capitalization | $49.21 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Roche Holding AG's assets below their book value (0.49x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Roche Holding AG's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Roche Holding AG (1998–2025)
The table below shows the annual total assets of Roche Holding AG from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF100.70 Billion ≈ $127.32 Billion |
-1.08% |
| 2024-12-31 | CHF101.80 Billion ≈ $128.70 Billion |
+12.53% |
| 2023-12-31 | CHF90.47 Billion ≈ $114.38 Billion |
+2.63% |
| 2022-12-31 | CHF88.15 Billion ≈ $111.45 Billion |
-4.51% |
| 2021-12-31 | CHF92.32 Billion ≈ $116.71 Billion |
+7.17% |
| 2020-12-31 | CHF86.14 Billion ≈ $108.90 Billion |
+3.67% |
| 2019-12-31 | CHF83.09 Billion ≈ $105.05 Billion |
+5.83% |
| 2018-12-31 | CHF78.52 Billion ≈ $99.27 Billion |
+2.40% |
| 2017-12-31 | CHF76.68 Billion ≈ $96.94 Billion |
-0.19% |
| 2016-12-31 | CHF76.82 Billion ≈ $97.12 Billion |
+1.39% |
| 2015-12-31 | CHF75.76 Billion ≈ $95.78 Billion |
+0.30% |
| 2014-12-31 | CHF75.54 Billion ≈ $95.50 Billion |
+21.51% |
| 2013-12-31 | CHF62.17 Billion ≈ $78.60 Billion |
-4.07% |
| 2012-12-31 | CHF64.81 Billion ≈ $81.93 Billion |
+5.24% |
| 2011-12-31 | CHF61.58 Billion ≈ $77.85 Billion |
+0.91% |
| 2010-12-31 | CHF61.02 Billion ≈ $77.15 Billion |
-18.17% |
| 2009-12-31 | CHF74.56 Billion ≈ $94.27 Billion |
-2.00% |
| 2008-12-31 | CHF76.09 Billion ≈ $96.20 Billion |
-2.68% |
| 2007-12-31 | CHF78.18 Billion ≈ $98.84 Billion |
+5.06% |
| 2006-12-31 | CHF74.41 Billion ≈ $94.08 Billion |
+7.28% |
| 2005-12-31 | CHF69.36 Billion ≈ $87.70 Billion |
+19.44% |
| 2004-12-31 | CHF58.08 Billion ≈ $73.42 Billion |
-2.37% |
| 2003-12-31 | CHF59.49 Billion ≈ $75.21 Billion |
-7.05% |
| 2002-12-31 | CHF63.99 Billion ≈ $80.91 Billion |
-15.00% |
| 2001-12-31 | CHF75.29 Billion ≈ $95.18 Billion |
+8.27% |
| 2000-12-31 | CHF69.53 Billion ≈ $87.91 Billion |
-1.27% |
| 1999-12-31 | CHF70.43 Billion ≈ $89.04 Billion |
+26.04% |
| 1998-12-31 | CHF55.88 Billion ≈ $70.65 Billion |
-- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more